Genetic Predisposition Links Lean and Obese MASLD to Similar Fibrosis Risk: Study

Published On 2025-11-14 14:30 GMT | Update On 2025-11-14 14:30 GMT

A new study published in Alimentary Pharmacology & Therapeutics has revealed that lean individuals with metabolic dysfunction–associated steatotic liver disease (MASLD) face a comparable risk of developing significant liver fibrosis as overweight or obese patients. The research highlights that genetic factors, rather than body weight alone, may play a critical role in determining fibrosis risk in MASLD. These findings challenge the traditional assumption that fibrosis severity is primarily linked to obesity and metabolic load, suggesting that lean MASLD should not be underestimated in clinical assessment.

The investigators conducted a detailed analysis of patients with MASLD across varying body mass index (BMI) categories, assessing fibrosis prevalence in relation to genetic risk scores (GRS). Results showed that individuals with higher GRS values demonstrated markedly higher rates of significant fibrosis compared to those with lower GRS. Importantly, the prevalence of fibrosis was consistent between lean and non-lean groups, underscoring that genetic susceptibility may override the influence of adiposity in fibrosis progression. This pattern suggests that genetic predisposition can serve as a more powerful predictor of disease advancement than traditional metabolic risk factors.

The study emphasizes the importance of integrating genetic profiling into MASLD evaluation to better stratify patients’ fibrosis risk. Routine liver monitoring and fibrosis assessment should extend to lean individuals with metabolic dysfunction, particularly those carrying higher genetic risk variants. By recognizing the genetic underpinnings of fibrosis progression, clinicians can implement more personalized management strategies, targeting those at greater risk regardless of body weight.

Keywords: Metabolic dysfunction–associated steatotic liver disease, MASLD, liver fibrosis, genetic risk score, lean MASLD, obesity, metabolic dysfunction, Alimentary Pharmacology & Therapeutics.

Reference (APA style):

Cozlea, A., Vonghia, L., Houben, T., et al. (2025). Genetic predisposition links lean and obese MASLD to similar fibrosis risk. Alimentary Pharmacology & Therapeutics. https://pubmed.ncbi.nlm.nih.gov/41147688/

Article Source : Alimentary Pharmacology & Therapeutics

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Shravani Dali

Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Genetic Predisposition Links Lean and Obese MASLD to Similar Fibrosis Risk: Study

Similar News

Seborrheic Dermatitis Linked to Epithelial Barrier Disorders Across Multiple Organs: JAMA

Low-Molecular-Weight Heparin not necessary in Early Lipid-Lowering for Hypertriglyceridemic Acute Pancreatitis: JAMA

Alembic Pharma bags USFDA nod for erosive esophagitis drug Dexlansoprazole Delayed Release

Children of Mothers With Anorexia Nervosa Face Higher Risk of Digestive Disorders: Study Finds

Surgery Alone May Cure Select Pancreatic Cancer Patients with Favorable Features: Study

Incretin-Based Diabetes Drugs Show No Added Risk of Pancreatitis but Slight Increase in Biliary Events, Study Finds

Novel therapies curb surgery for ulcerative colitis, study suggests